Ann: Imugene Opens First Australian Site for azer-cel Trial, page-42

Its a update on the existing trail, Patients in the trial are being recruited across 15 leading cancer centres in the U.S. including, Columbia University, University of Minnesota, Emory, and Moffitt Cancer Centres and plans are ongoing to open up to 5 sites in Australia. they started dosing in Australia, they just provided the news, The Royal Prince Alfred Hospital in Sydney will begin patient recruitment in November 2024

In September 2024, Imugene reported promising results from this trial, with three out of ten patients achieving complete responses. Notably, the first two patients in Cohort B maintained their complete responses for over 120 and 90 days, respectively

why RPA is significant addition and I can see why IMU is happy on this start of clinical trials

1. in 2019, RPA was approved to provide CAR T-cell therapy services, establishing a multidisciplinary clinical program for the collection and cryopreservation of these cells.
2. RPA has been involved in clinical trials for pembrolizumab, an immunotherapy drug used to treat various cancers. A seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma included contributions from RPA researchers

This is a significant achievement, hope these bunch of nerds can get a proper social media manager and get this out properly, but hey if the product is awesome who cares right